GHK-Cu vs Sermorelin
Side-by-Side Comparison
| Attribute | Ghk Cu | Sermorelin |
|---|---|---|
| Category | Skin & Tissue Repair | Growth Hormone Secretagogue |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. |
| Evidence Rating | F — No Regulatory Activity | C — Phase I–II Clinical Trials |
| Clinical Status | Available in cosmetic formulations; no drug approval | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Safety Profile | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) |
| Route | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) | Subcutaneous |
| Dose Range | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area | 100–300 mcg/day SC |
| Frequency | SC: Once daily; Topical: 1–2x daily | Once daily (typically before bed) |
| Molecular Weight | ~403.9 g/mol | ~3357.9 g/mol |
| Half-Life | ~30 minutes plasma | ~10–20 minutes |
Overview
GHK-Cu and Sermorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
GHK-Cu is also researched for: Skin Health, Wound Healing.
Sermorelin is also researched for: Body Composition, Sleep.
Safety Considerations
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Related Products
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Related Research News
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
GHK-Cu: Copper Peptide in Tissue Repair and Skin Research
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, stands out as a naturally occurring peptide central to human tissue maintenance and repair. Found in plasma, saliva, urine, and skin, its levels drop from about 200 ng/mL in young adults with age, linking to reduced regeneration. Preclinical studies highlight its roles in collagen production, wound healing, angiogenesis, anti-inflammation, and more, with the copper complex showing greater potency than unbound GHK.
Glow Blend: GHK-Cu, BPC-157 & TB-500 Peptide Research
Glow Blend combines GHK-Cu, BPC-157, and TB-500 in a 70mg multi-peptide formulation studied for skin biology, tissue repair, and cellular processes. Each component targets overlapping areas like collagen pathways, connective tissue response, and cell migration. This guide explains their research roles, molecular details, and why they pair together in regenerative studies.